Xencor Shares Jump 20% to 52-Week High as Kidney Cancer Drug XmAb819 Shows 45.5% Response Rate in Early Trial

Xencor Inc. shares rose 20% to a 52-week high after presenting early trial data showing its kidney cancer drug XmAb819 shrank tumors in 45.5% of patients. The stock reached $30.12, with a market value of $2.25 billion. The company plans to discuss accelerated approval with the FDA in 2027. Analysts' price targets were exceeded, with Wedbush at $30 and Truist at $29.

Original reporting
Published Oct 26, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Xencor Shares Jump 20% to 52-Week High as Kidney Cancer Drug XmAb819 Shows 45.5% Response Rate in Early Trial — source image
Decision brief

The 30-second read

$XNCRBullishMed
01

Why it matters

The disclosed efficacy and dose-selection support for Phase 3, plus plans to discuss an accelerated approval pathway with the FDA in early 2027, are likely to drive incremental repricing of clinical success odds.

02

Market read

Traders get a same-week catalyst from ESMO-linked clinical data, including quantified ORR and explicit Phase 3 dose designation language.

03

What to watch

The article does not provide safety/tolerability details, durability beyond six months, or biomarker response rates, which can materially change the probability-weighted outlook for accelerated approval and Phase 3 success.

Relevance 8/10Novelty 8/10Timing: pre-market Monday follow-through after Sunday ESMO presentation and investor webcast

Background

XmAb819 is a bispecific antibody targeting ENPP3 on tumor cells and CD3 on immune T cells, being developed for advanced clear cell renal cell carcinoma.

Company-level read

Ticker impact

$XNCRBullishMedium confidence
Context

Xencor shares jumped after early Phase 1 data for XmAb819 showed a 45.5% confirmed objective response rate in 11 evaluable patients and supported a proposed Phase 3 dose.

Expected impact

Likely near-term upside pressure as traders price higher probability of successful Phase 3 and potential accelerated-approval discussions.

Evidence & confidence

The article cites specific efficacy metrics (45.5% ORR, 82% progression-free at six months) and states management will use the 400 mcg/kg dose for Phase 3, which is a direct catalyst for sentiment and valuation, despite the small cohort.

Market effects

Reinforces investor appetite for ENPP3-targeting bispecific T-cell engagers in solid tumors, potentially lifting sentiment across the solid-tumor bispecific peer group.

Primarily US Nasdaq biotech sentiment; broader markets were mixed ahead of the Fed decision.

ESMO conference data flow can shift global biotech risk appetite, especially for oncology immunotherapy platforms.

Counterpoint

Phase 1 results on only 11 evaluable patients may not translate to Phase 3, so the stock could retrace if later cohorts show lower response rates or safety issues.

Key entities

  • Xencor Inc.

    Nasdaq-listed biotech whose XmAb819 early Phase 1 data triggered a sharp share move.

  • XmAb819

    ENPP3 x CD3 bispecific antibody in Phase 1 for advanced clear cell renal cell carcinoma.

  • U.S. Food and Drug Administration (FDA)

    Planned discussion in early 2027 about a possible accelerated approval pathway.

  • European Society for Medical Oncology (ESMO) Congress

    Venue where updated Phase 1 results were presented before the Monday open.

Related articles

$XNCRMedAI 8/10

Xencor reports early trial data for autoimmune therapies

Xencor Inc. (XNCR) shared early Phase 1b trial data for plamotamab in rheumatoid arthritis patients, showing significant B-cell reduction and clinical improvements. The study reported adverse events like pyrexia and cytokine release syndrome. Xencor also updated on XmAb657, with plans to start trials in severe autoimmune diseases in Q1 2027.

$XNCRHighAI 8/10

Xencor Reports Third Quarter 2026 Financial Results

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor Reports Third Quarter 2026 Financial Results -- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO -- -- Early dose-escalation data fo

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.